Abstract
Ameliorating graft injury induced by ischemia and hypoxia, expanding the donor pool, and improving graft quality and recipient prognosis are still goals pursued by the transplant community. The preservation of organs during this process from donor to recipient is critical to the prognosis of both the graft and the recipient. At present, static cold storage, which is most widely used in clinical practice, not only reduces cell metabolism and oxygen demand through low temperature but also prevents cell edema and resists apoptosis through the application of traditional preservation solutions, but these do not improve hypoxia and increase oxygenation of the donor organ. In recent years, improving the ischemia and hypoxia of grafts during preservation and repairing the quality of marginal donor organs have been of great concern. Hemoglobin-based oxygen carriers (HBOCs) are “made of” natural hemoglobins that were originally developed as blood substitutes but have been extended to a variety of hypoxic clinical situations due to their ability to release oxygen. Compared with traditional preservation protocols, the addition of HBOCs to traditional preservation protocols provides more oxygen to organs to meet their energy metabolic needs, prolong preservation time, reduce ischemia–reperfusion injury to grafts, improve graft quality, and even increase the number of transplantable donors. The focus of the present study was to review the potential applications of HBOCs in solid organ preservation and provide new approaches to understanding the mechanism of the promising strategies for organ preservation.
Highlights
Solid organ transplantation (SOT) is an optimal, lifesaving treatment choice for patients with endstage organ failure
Standard preservation solutions are currently used for static cold preservation, the repair and evaluation of marginal organs may rely on multiple combinations of MP, oxygenation strategies, and temperature regulation
Many efforts have been made by clinical practitioners and researchers to explore ways to mitigate graft ischemia–reperfusion injury, improve graft quality, and increase recipient and graft survival rates
Summary
Solid organ transplantation (SOT) is an optimal, lifesaving treatment choice for patients with endstage organ failure. HBOCs lowered the peak of serum creatinine, reduced kidney inflammation levels, and maintained structural integrity; improved survival and function; and slowed the advance of interstitial fibrosis Cells preserved better with HEMO2Life in a oxygenation and provided SOD activity
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have